Stockscreener 앱 받기
0.871
1.05%
-0.0092
시간 외 거래:
.88
0.009
+1.03%
전일 마감가:
$0.8802
열려 있는:
$0.88
하루 거래량:
243.57K
Relative Volume:
0.77
시가총액:
$25.87M
수익:
-
순이익/손실:
$-10.21M
주가수익비율:
-1.4909
EPS:
-0.5842
순현금흐름:
-
1주 성능:
+22.71%
1개월 성능:
-25.56%
6개월 성능:
-54.40%
1년 성능:
-28.02%
1일 변동 폭
$0.825
$0.90
1주일 범위
$0.6801
$0.90
52주 변동 폭
$0.6801
$2.60
Neurosense Therapeutics Ltd Stock (NRSN) Company Profile
NRSN을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
NRSN
Neurosense Therapeutics Ltd
|
0.871 | 26.14M | 0 | -10.21M | 0 | -0.5842 |
|
VRTX
Vertex Pharmaceuticals Inc
|
468.38 | 113.87B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.54 | 80.22B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
406.40 | 52.56B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
803.74 | 49.31B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
175.07 | 37.37B | 447.02M | -1.18B | -906.14M | -6.1812 |
Neurosense Therapeutics Ltd 주식(NRSN)의 최신 뉴스
NeuroSense Shareholders Approve Equity Grants to Directors and CEO to Preserve Cash - TipRanks
NeuroSense Therapeutics (NASDAQ:NRSN) Upgraded by Wall Street Zen to Hold Rating - Defense World
NeuroSense Therapeutics Ltd. (NASDAQ:NRSNW) Short Interest Down 15.5% in December - Defense World
NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) Given Consensus Rating of “Moderate Buy” by Brokerages - Defense World
Weekly Buzz: FDA OKs Roche's Lunsumio VELO; It's No For Tolbrutinib; BioMarin, SNY Open Wallets - RTTNews
NeuroSense Confirms Favorable Safety and Tolerability of PrimeC in an Alzheimer's Phase 2 Study - Sahm
NeuroSense Unveils Favourable Safety Analysis Data Of PrimeC In NST-AD-001 Study For Alzheimer's - Nasdaq
NeuroSense Therapeutics (NASDAQ:NRSN) Receives Buy Rating from D. Boral Capital - Defense World
D. Boral Capital Maintains NeuroSense Therapeutics (NRSN) Buy Recommendation - Nasdaq
NeuroSense Reports Favorable Safety Profile for PrimeC in Phase 2 Alzheimer’s Trial - TipRanks
Neurosense stock rises as Alzheimer’s drug shows favorable safety profile By Investing.com - Investing.com South Africa
Neurosense stock rises as Alzheimer’s drug shows favorable safety profile - Investing.com
Experimental Alzheimer's combo shows no serious side effects in trial - Stock Titan
Why NeuroSense Therapeutics Ltd. Equity Warrant stock appeals to analysts2025 Bull vs Bear & Low Risk High Reward Trade Ideas - Улправда
Forecast Cut: Why NeuroSense Therapeutics Ltd. Equity Warrant stock appeals to analystsBuy Signal & Daily Momentum Trading Reports - Улправда
Rally Mode: Is Capella Minerals Limited (N7D) stock worth buying before Fed actionEarnings Overview Summary & Safe Capital Investment Plans - moha.gov.vn
Will NeuroSense Therapeutics Ltd. stock pay special dividends2025 Volume Leaders & Verified Swing Trading Watchlists - Улправда
How NeuroSense Therapeutics Ltd. stock benefits from tech adoption2025 Volatility Report & Reliable Volume Spike Trade Alerts - Улправда
Is NeuroSense Therapeutics Ltd. stock resilient to inflationRate Hike & Weekly Momentum Stock Picks - Bölüm Sonu Canavarı
ETF Watch: Can NeuroSense Therapeutics Ltd. (H1Z) stock sustain institutional flowsJuly 2025 Recap & Fast Gain Swing Trade Alerts - DonanımHaber
How NeuroSense Therapeutics Ltd. (H1Z) stock compares with tech leaders2025 Stock Rankings & Low Volatility Stock Suggestions - Улправда
How NeuroSense Therapeutics Ltd. stock compares to growth peersJuly 2025 Technicals & AI Based Trade Execution Alerts - Улправда
It had formed inverted head and shoulders earlier soon it gave a break out of the pattern.2025 Historical Comparison & High Conviction Buy Zone Alerts - Bollywood Helpline
NeuroSense Regains Compliance with Nasdaq's Minimum Equity Requi - GuruFocus
Whale Trades: What dividend safety rating applies to NeuroSense Therapeutics Ltd H1Z stockJuly 2025 Fed Impact & Weekly High Conviction Trade Ideas - moha.gov.vn
NeuroSense Therapeutics Schedules Shareholder Meeting to Approve Equity Compensation - MSN
Wall Street Zen Downgrades NeuroSense Therapeutics (NASDAQ:NRSN) to Sell - Defense World
Amyotrophic Lateral Sclerosis Market Outlook: Expanding Therapeutic Pipeline and Novel Drug Launches Propel Growth Throughout Forecast Period (2025-2034) | DelveInsight - Yahoo Finance
A better buy-in window may exist right now for Lexicon Pharmaceuticals Inc (LXRX) - setenews.com
NRSN: PARAGON phase III ALS trial starts mid-2026, with strong data, FDA clearance, and global scope - TradingView — Track All Markets
NRSN: Global phase III ALS trial set for mid-2026, with strong efficacy and active partnership talks - TradingView — Track All Markets
NeuroSense Completes Data Collection for Alzheimer’s Trial - TipRanks
NeuroSense (NRSN) locks RoAD Phase 2 Alzheimer’s trial database, eyes Q1 2026 data - Stock Titan
12 Health Care Stocks Moving In Monday's Intraday Session - Benzinga
Will NeuroSense Therapeutics Ltd. (H1Z) stock outperform value peersEarnings Summary Report & Daily Oversold Stock Bounce Ideas - Newser
How strong is NeuroSense Therapeutics Ltd. Equity Warrant stock balance sheetMarket Performance Report & Verified Short-Term Trading Plans - Newser
NeuroSense to Hold Pre-NDS Meeting with Health Canada in April 2026 - Nasdaq
NeuroSense Therapeutics LtdResuming regulatory advancement in Canada for PrimeC in amyotrophic lateral sclerosis - marketscreener.com
NeuroSense Therapeutics Plans Pre-NDS Meeting with Health Canada for ALS Drug - TipRanks
Neurosense Therapeutics LtdResuming Regulatory Advancement In Canada For Primec In Amyotrophic Lateral Sclerosis - TradingView
Is NeuroSense Therapeutics Ltd. stock overvalued by current metricsMarket Growth Review & Capital Protection Trading Alerts - Newser
How interest rate cuts could boost NeuroSense Therapeutics Ltd. Equity Warrant stockWeekly Trade Summary & AI Enhanced Trade Execution Alerts - Newser
NeuroSense (NASDAQ: NRSN) plans April 2026 Health Canada pre-NDS as it eyes mid-2026 NDS - Stock Titan
NeuroSense Therapeutics (NRSN) Stock Analysis Report | Financials & Insights - Benzinga
What downside risks could hit NeuroSense Therapeutics Ltd. (H1Z) stockPortfolio Value Summary & Risk Managed Investment Signals - Newser
Aug EndMonth: How NeuroSense Therapeutics Ltd stock compares to growth peersWeekly Investment Report & Risk Managed Investment Strategies - BỘ NỘI VỤ
Is NeuroSense Therapeutics Ltd H1Z a good long term investmentMean Reversion Trades & High Return Capital Strategies - earlytimes.in
NeuroSense: PrimeC Produces Statistically Significant Reductions in Alzheimer's Disease Biomarkers (PR Newswire) - Aktiellt
Award-Winning Broadway, Television & Film Star Aaron Lazar Featuring NeuroSense CEO Alon Ben-Noon in a Special Live Podcast on ALS Science, PrimeC's Commercialization Strategies, and Community (PR Newswire) - Aktiellt
Hedge Fund Moves: How NeuroSense Therapeutics Ltd. stock compares to growth peers2025 Bull vs Bear & Proven Capital Preservation Methods - moha.gov.vn
NeuroSense Therapeutics (NASDAQ:NRSN) Given “Buy” Rating at D. Boral Capital - Defense World
Neurosense Therapeutics Ltd (NRSN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.52%
0.07%
자본화:
|
볼륨(24시간):